Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics
RCUS Price/Volume Stats
| Current price | $9.97 | 52-week high | $18.98 |
| Prev. close | $9.63 | 52-week low | $6.50 |
| Day low | $9.66 | Volume | 843,700 |
| Day high | $10.10 | Avg. volume | 1,081,576 |
| 50-day MA | $8.42 | Dividend yield | N/A |
| 200-day MA | $13.11 | Market Cap | 1.06B |
RCUS Stock Price Chart Interactive Chart >
Arcus Biosciences, Inc. (RCUS) Company Bio
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.
RCUS Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RCUS Price Returns
| 1-mo | 16.88% |
| 3-mo | 4.07% |
| 6-mo | -42.93% |
| 1-year | -35.68% |
| 3-year | -57.79% |
| 5-year | -65.57% |
| YTD | -33.04% |
| 2024 | -22.04% |
| 2023 | -7.64% |
| 2022 | -48.90% |
| 2021 | 55.89% |
| 2020 | 157.03% |